GlassScriptPhysician profile
Monica Beas
NPI 1558049874
$4,460.51
in general payments reported to CMS, 2019-2025
24 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $498 · 2024: $1,459 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,204.21 |
| Education | $256.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $558.30 | 2024-2025 | Tremfya |
| Abbvie INC. | $451.80 | 2024-2025 | |
| Pfizer INC. | $402.45 | 2023-2025 | |
| Incyte Corporation | $344.83 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $320.43 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $297.97 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $293.25 | 2023-2025 | Dupixent |
| Ucb, INC. | $256.90 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $208.27 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $207.68 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $194.54 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $174.41 | 2024-2025 | Cabtreo, Jublia, Siliq |
| Arcutis Biotherapeutics, INC. | $158.21 | 2024-2025 | Zoryve |
| Organon LLC | $135.06 | 2025 | Vtama, Nexplanon |
| Dermavant Sciences, INC. | $123.34 | 2023-2024 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $91.41 | 2024 | Sotyktu |
| Kerecis Limited | $49.69 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Amgen INC. | $47.55 | 2024 | Otezla |
| Botanix Sb INC | $44.27 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.54 | 2025 | Spevigo |
| Convatec INC. | $24.09 | 2024 | |
| Medimetriks Pharmaceuticals, INC. | $15.48 | 2025 | |
| Verrica Pharmaceuticals INC. | $14.61 | 2024 | Ycanth |
| Almirall LLC | $14.43 | 2024 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Beas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.